In a research note published August 11, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Peregrine Pharmaceuticals (PPHM) with …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Peregrine Pharmaceuticals, Inc. (PPHM) and a $5 price target.
